Study of GB268 alone or with other drugs for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called GB268, either alone or with other treatments, for people with advanced breast cancer that has not responded to previous therapies. It aims to find out if GB268 can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of breast cancer called triple-negative or HR+/HER2- that has spread and cannot be removed by surgery.
- You must not have had certain previous treatments, depending on the specific study group.
- You must have at least one tumor that can be measured on scans.
- You must be generally healthy enough for daily activities (ECOG score 0 or 1).
- You must provide a tumor tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GB268, which targets three different proteins (PD-1, CTLA-4, and VEGF) that help tumors grow and hide from the immune system. It is for people with advanced solid tumors who have tried standard treatments, or for whom no standard treatment is available.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Hear when a new Breast Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.